版塊導(dǎo)航: 正在加載中...

登錄注冊

應(yīng)《網(wǎng)絡(luò)安全法》要求，自2017年10月1日起，未進(jìn)行實(shí)名認(rèn)證將不得使用互聯(lián)網(wǎng)跟帖服務(wù)。為保障您的帳號能夠正常使用，請盡快對帳號進(jìn)行手機(jī)號驗(yàn)證，感謝您的理解與支持！

24小時熱門版塊排行榜

北京石油化工學(xué)院2026年研究生招生接收調(diào)劑公告

返回列表

本帖產(chǎn)生 1 個翻譯EPI ，點(diǎn)擊這里進(jìn)行查看

小丸丸9

鐵蟲 (正式寫手)

應(yīng)助: 0 (幼兒園)
金幣: 777.5
散金: 77
紅花: 1
帖子: 829
在線: 147.5小時
蟲號: 3337955
注冊: 2014-07-24
性別: MM
專業(yè): 無機(jī)藥物化學(xué)

[求助] 求翻譯一篇摘要，謝謝

Longterm
safety and efficacy data generated in Europe from usage of fumaric acid formulations
in the latter disease constituted grounds to investigate their effects in MS patients. Dimethyl
fumarate (DMF) was found to be the active principle in those formulations and in vitro studies
have demonstrated that DMF has immune-modulatory properties exerted through abilities
to divert cytokine production toward a Th2 profile, both on lymphocytes and microglial cells.
More importantly, DMF was discovered to impact the anti-oxidative stress cell machinery
promoting the transcription of genes downstream to the activation of the nuclear factor
(erythroid derived 2)-like2 (NRF2). DMF exposure increases the cytosol concentrations of
NRF2, which besides immune regulatory effects, has the potential for cytoprotection on glial
cells, oligodendrocytes and neurons. Extensive and rigorous clinical trials have assessed the
efficacy and safety of DMF at the dose of 240 mg twice and three times a day in relapsingremitting
MS patients during one phase IIb and two phase III trials. Robust, positive results
were obtained across a number of clinical and paraclinical parameters. In one study (DEFINE),
the relative reductions of the adjusted annualized relapse rate of the low and high dose
regimens in comparison with placebo were 53% and 48%, respectively (p < 0.001 for both
comparisons). In the other trial (CONFIRM), DMF decreased the annualized relapse rate in
comparison with placebo by 44% in the lower and by 51% in higher dosage group (also
p < 0.001). The number and size of lesions as detected by magnetic resonance imaging were
also significantly decreased in comparison with the patients receiving DMF at every dosage.
Multiple post hoc and subgroup analyses corroborated the clinical data, rendering DMF an
appealing medication whose potential for impacting the degenerative aspects of MS remains
to be explored.

回復(fù)此樓

» 猜你喜歡

材料考研調(diào)劑已經(jīng)有7人回復(fù)
270調(diào)劑已經(jīng)有7人回復(fù)
275學(xué)碩081000服從調(diào)劑到其他專業(yè)，保不住本專業(yè)了已經(jīng)有6人回復(fù)
0710生物學(xué)，325求調(diào)劑已經(jīng)有3人回復(fù)
296材料專碩求調(diào)劑已經(jīng)有5人回復(fù)
385分生物學(xué)（071000）求調(diào)劑已經(jīng)有5人回復(fù)
377求調(diào)劑已經(jīng)有3人回復(fù)
【求調(diào)劑】新能源材料本科，一志愿211，初試321 已經(jīng)有6人回復(fù)
316求調(diào)劑已經(jīng)有11人回復(fù)
321求調(diào)劑已經(jīng)有9人回復(fù)

大家好

1樓 2015-06-03 10:48:20

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

baoshanqiu

至尊木蟲 (著名寫手)

翻譯EPI: 204
應(yīng)助: 103 (高中生)
金幣: 15293.5
紅花: 41
帖子: 1611
在線: 431.6小時
蟲號: 3856202
注冊: 2015-05-08
性別: GG
專業(yè): 胃腸道免疫相關(guān)疾病

【答案】應(yīng)助回帖

★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
小丸丸9: 金幣+50, 翻譯EPI+1, 雖然翻譯得不怎么好，不過辛苦了。謝謝 2015-06-04 10:15:46

長期
歐洲使用延胡索酸配方治療晚期疾病得到的安全和有效性的資料成為研究該類配方對多發(fā)性硬化癥療效的基礎(chǔ)。二甲基延胡索酸（DMF)是該類配方的主要活性成分。體外使用表明，DMF 具有免疫調(diào)節(jié)特性，表現(xiàn)為能歧化淋巴細(xì)胞和小膠質(zhì)細(xì)胞的細(xì)胞因子產(chǎn)生朝Th2方向。更重要的是DMF能動員抗氧化應(yīng)激細(xì)胞機(jī)制提高激活核因子（紅細(xì)胞樣衍化因子2）（NRF2)下游基因轉(zhuǎn)錄活性。膠質(zhì)細(xì)胞、少突細(xì)胞和神經(jīng)元暴露于DMF后，細(xì)胞質(zhì)NRF2濃度升高。這不僅具有免疫調(diào)節(jié)作用，還具有保護(hù)細(xì)胞的潛能。廣泛而嚴(yán)格的臨床試驗(yàn)已證實(shí)了DMF 的療效和安全性。在一個IIb和兩個III期臨床試驗(yàn)中DMF在240mg，每天2次和3次的劑量可延遲多發(fā)性硬化癥病人的復(fù)發(fā)。在許多臨床和亞臨床參數(shù)中得到穩(wěn)定的陽性結(jié)果。在一項(xiàng)研究（確定）中，低劑量和高劑量組與安慰劑組比較，調(diào)整的年復(fù)發(fā)率相對減少，分別為53%和48% （二者比較均p<0.001).在另一個臨床試驗(yàn)（確認(rèn)）中，DMF組與安慰劑組比較減少年復(fù)發(fā)率在低劑量為44%，高劑量為51%（也是p<0.001)。在每一個劑量下接受DMF的病人經(jīng)核磁共振成像檢測損傷的數(shù)量和大小都顯著降低。多次隨訪和子群分析確證了臨床資料，使DMF成為有希望的治療藥物。它對多發(fā)性硬化癥變性方面的影響有待進(jìn)一步探索。

贊一下

回復(fù)此樓

2樓2015-06-04 00:20:38

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

相關(guān)版塊跳轉(zhuǎn) 我要訂閱樓主小丸丸9 的主題更新